AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06457581 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling
Description: Group A will undergo dry needling sessions twice a week over eight weeks, specifically targeting trigger points and tender points. Simultaneously, a consistent dosage of selective serotonin reuptake inhibitor (SSRI) will be administered and maintained throughout the entire duration of the study.
Study NCT06457581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger points injections
Description: Group B will undergo a comprehensive intervention involving trigger point injections administered biweekly over eight weeks. These injections will specifically target trigger points. Additionally, a control measure will be implemented through simulated needling at non-specific points.
Study NCT06457581 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: serotonin reuptake inhibitor (SSRI)
Description: serotonin reuptake inhibitor (SSRI)
Study NCT05792735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab Injection
Description: Cadonilimab, an anti-CTLA-4/PD-1 bispecific antibody, at a dose of 6mg/kg is given in combination with chemotherapy every 2 weeks preoperatively and postoperatively.
Study NCT05792735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Preoperative short-course radiotherapy (5x5 Gy)
Study NCT05792735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
Study NCT04864444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
Study NCT04864444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
Study NCT05552911 — intervention group
Intervention type: PROCEDURE
Intervention: Pretreatment strategies before drug balloon therapy
Description: Preconditioning strategies for the treatment of in de novo coronary lesions using drug-coated balloons.
Study NCT05552911 — intervention group
Intervention type: PROCEDURE
Intervention: Different types of in-stent restenosis were treated with drug-coated balloons
Description: A new classification method of ISR lesions was proposed to observe the clinical prognosis of different ISR lesions treated with drug-coated balloon.
Study NCT06537843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Study NCT06537843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Injection
Description: Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Study NCT06537843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Study NCT04902846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
Study NCT04902846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
Study NCT05618743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done
Study NCT05456477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef
Description: Beef entrees
Study NCT05456477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Poultry
Description: Poultry entrees
Study NCT04677348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Description: ultrasound-guided PENG block with 0.3% ropivacaine 20cc
Study NCT04677348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block (FICB)
Description: ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
Study NCT06208020 — intervention group
Intervention type: OTHER
Intervention: Functional near-infrared spectroscopy (fNIRS) detection
Description: fNIRS( NirScan Danyang Huichuang Medical Equipment Co. Ltd., China) will be used to detect changes in HbO and HbR during rest and voluntary swallowing. The swallowing procedure will be used consisted of three phases of manipulations: 30-s resting state periods, 30-s swallowing periods and 30-s resting state periods. A pre-collection will be conducted before the formal collection so that the subjects could understand the test process. After the pre-collection, the subjects will take a rest for 5 minutes before the formal collection.
Study NCT04596475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir (GLE/PIB)
Description: The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
Study NCT04549701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVAL US-guided Therapy
Description: Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
Study NCT04549701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care will be provided.
Study NCT04549701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care will be provided.
Study NCT05698680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg Tablet
Description: See treatment arm Prednisolone
Study NCT05698680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg Oral Tablet
Description: See treatment arm Colchicine
Study NCT04436146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laryngeal manual therapies
Description: The laryngeal manual therapy incorporates massaging the laryngeal muscles thus reducing excessive tension in the laryngeal and perilaryngeal musculature in patients with globus .
Study NCT05269290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®, syrup, 30 mg/5 ml
Description: A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
Study NCT05269290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once a day on top of standard therapy.
Study NCT06458933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sage
Description: Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).
Study NCT06458933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Individual Psychotherapy
Description: Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
Study NCT04894656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy
Description: Tests to assess intestinal permeability
Study NCT04894656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Labs, urine tests, upper endoscopy with biopsy and confocal laser endomicroscopy
Description: Tests to assess intestinal permeability
Study NCT05172739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-Based Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Study NCT05172739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-free Anesthesia-Analgesia Strategy
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Study NCT05339672 — intervention group
Intervention type: OTHER
Intervention: Blood sampling - Pharmacokinetic assessment
Description: Two pharmacokinetic assessements will be performed (before start of enzalutamide and 4-6 weeks after start of enzalutamide). Each pharmacokinetic assessment consists of 9 samples (3mL blood)
Study NCT05244681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
Study NCT05720780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MS group
Description: All patients will perform the usual training by listening a piece of music of the same duration as the training. The patient will be able to choose among 4 different musical proposals corresponding to 4 different styles: rock, modern, jazz and classical. The song chosen by the patient will be the musical support for all the sessions of training on the cycle ergometer. The musical pieces will be composed with a constant rhythm (bpm=60) which, from a tonal point of view, will echo the pedaling movement. The constant rhythm will be superimposed on musical patterns in the form of loops in the styles mentioned. The musical support will assume a priming (activation) and dragging (synchronization) function, facilitating movement planning/synchronization and creating a pleasant context in which to carry out training
Study NCT05720780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C group
Description: All patients will perform 12 to 14 supervised sessions depending on the center they belong to (5-6 sessions/week) each consisting of 30 minutes of exercise at the cycle ergometer plus 3 minutes of warm-up and 3 minutes of recovery. After a warm-up phase at 0 W, the initial workload will be set to 60% of the theoretical maximum. Intensity increases or decreases of 10 W will be made according to the criteria of Maltais et al (workload will be increased when patients will report dyspnea and/or leg fatigue as ≤3 on a Borg scale modified to 10 points of perceived effort. The training load will remain unchanged if the Borg score is 4 or 5 and will be reduced for scores ≥6). Patients will have to maintain a pedaling frequency between 55 and 60 rpm.
Study NCT05458414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-operative Navigation System
Description: In the experimental group，a navigation technology was used to identify tumor margins during the surgery.
Study NCT05178732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose of protein
Description: One of three protein doses provided
Study NCT05178732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phase
Description: Different phase of the menstrual cycle
Study NCT05872776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation with RR2 device
Description: non-invasive neuromodulation with RR2 device
Study NCT05872776 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock sham neuromodulation with sham RR2 device
Description: Mock sham stimulation with RR2 device
Study NCT04746768 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: exercise and nutritional support
Description: exercise and nutritional support program during an active support phase (0 to 6 months) followed by an empowerment phase (from 6 to 12 months)
Study NCT04747171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal Magnesium
Description: intrathecal adjuvants to bupivacaine
Study NCT04747171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal dexamthasone
Description: intrathecal adjuvants to bupivacaine
Study NCT04747171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal dexmedetomidine
Description: intrathecal adjuvants to bupivacaine
Study NCT06463067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: playing mobile game
Description: Changes in anxiety levels were measured by playing a mobile game to children before dental examination.
Study NCT06463067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: reading book
Description: Changes in anxiety levels were measured by reading books to children before dental examination.
Study NCT06463067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: watching video
Description: Changes in anxiety levels were measured by showing a video to children before dental examination.
Study NCT06463067 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: tell-show-do group
Description: Before the dental examination, the tell-show-do technique was applied to the children and the changes in their anxiety levels were measured.
Study NCT05462210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Protocol Assisted with Simulated Clinical Immersion Videos
Description: Mobilization Protocol Assisted with Simulated Clinical Immersion Videos Simulated clinical immersion videos created for the mobilization protocol for patients in the intervention group will be sent to their smartphones once they are admitted to the clinic. The videos prepared within the scope of the mobilization protocol will be watched by patients in company with the researcher the day before the operation, their questions will be answered, and the correct mobilization techniques will be shown practically. It is expected that patients watch the videos at least four times, as twice with the researcher and twice by themselves.
Study NCT04971005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Autologous Hematopoietic Stem Cell Transplantation
Study NCT04971005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: 600 mg every 6 months continuously
Study NCT04971005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: 12 mg/day for 5 consecutive days and again after 365 days for 3 days
Study NCT05210179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TURKOVAC-Dollvet
Description: TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
Study NCT05210179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TURKOVAC-Koçak
Description: TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
Study NCT05429294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients with HER2-positive advanced/metastatic breast cancer are treated with pyrotinib combined with trastuzumab and albumin paclitaxel in the first-line setting.
Study NCT05399459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant 25 MG
Description: Single dose of 25 mg orally disintegrating tablet of rimegepant
Study NCT05399459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 MG
Description: Single dose of 75 mg orally disintegrating tablet of rimegepant
Study NCT05399459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT05248438 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study NCT06229951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day
Study NCT06229951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control patients will take placebo 2 tabs a day.
Study NCT05582642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Study NCT05582642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training (IMT)
Description: The training itself includes 2 x 30 breathing cycles per day. The whole training should take place daily, 7 days a week. The initial training intensity in the treatment arm (resistance of the respiratory muscle training) is set to 50% of the maximum respiratory muscle strength (measured using PImax). Once a week the present investigators get a picture of patient's training, pay attention to shortness of breath, potential for adaptation.~In the control arm of the study, this force adjustment would not take place, i.e. it is an endurance training of the diaphragm (10% of PI Max over the whole 6 weeks) with, however, also the control dates of the training twice a week. At least in the 6 weeks of the study (see above).
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: For BNT162b2 subjects
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V002 30 µg
Description: For BNT162b2 subjects
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
Description: For BNT162b2 subjects
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 30 µg
Description: For BBIBP-CorV or CoronaVac subjects
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V002 30 µg
Description: For BBIBP-CorV or CoronaVac subjects
Study NCT05788185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration
Description: For BBIBP-CorV or CoronaVac subjects
Study NCT04823949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Description: See arm description